What is the difference between adjuvant and neoadjuvant treatment for Endometrial Cancer

Adjuvant vs. Neoadjuvant Treatment for Endometrial Cancer

Great question—understanding the timing and purpose of these treatments is important for your care decisions.

The Key Difference: Timing

Neoadjuvant treatment = given BEFORE surgery Adjuvant treatment = given AFTER surgery

Think of it this way: neoadjuvant therapy tries to shrink the tumor before your surgeon removes it, while adjuvant therapy works to eliminate any remaining cancer cells after surgery.

---

NEOADJUVANT TREATMENT (Before Surgery)

Purpose:

• Shrink the tumor to make surgery easier and more effective
• Reduce the size and extent of disease before removal
• Potentially improve surgical outcomes

When it's used:

• Locally advanced endometrial cancer
• When the tumor is large or has spread to nearby tissues
• To make inoperable tumors operable

Typical approaches:

• Chemotherapy (often platinum-based combinations)
• Radiation therapy
• Sometimes hormone therapy (for specific endometrial cancer types)

---

ADJUVANT TREATMENT (After Surgery)

Purpose:

• Eliminate microscopic cancer cells that may remain after surgery
• Reduce the risk of recurrence (cancer coming back)
• Improve long-term survival

When it's used:

• After hysterectomy (surgical removal of the uterus)
• Based on pathology findings (what the pathologist finds in the removed tissue)
• Risk factors like stage, grade, and molecular characteristics

Typical approaches:

• Chemotherapy
• Radiation therapy (vaginal brachytherapy or external beam)
• Hormone therapy (for hormone-sensitive endometrial cancers)
• Immunotherapy (for specific molecular subtypes like MSI-High or dMMR)

---

How Doctors Decide Which Approach

According to NCCN Guidelines for Endometrial Cancer, your oncologist considers:

1. Stage at diagnosis - How far the cancer has spread
2. Histology and grade - The type and aggressiveness of cancer cells
3. Molecular testing - Biomarkers like:
   • MSI-High/dMMR (mismatch repair deficiency) - may benefit from immunotherapy
   • POLE mutations - associated with better prognosis
   • TP53 mutations - associated with more aggressive disease
4. Your overall health - Ability to tolerate treatment

---

Important Questions to Ask Your Oncologist

1. What is the stage and grade of my endometrial cancer?
2. Has molecular testing been done on my tumor? (MSI, POLE, TP53 status)
3. Do you recommend neoadjuvant treatment before surgery, or adjuvant treatment after?
4. What are the specific goals of the treatment you're recommending?
5. What are the potential side effects, and how will we manage them?
6. Are there clinical trials available for my specific cancer type?

---

Key Takeaway

The choice between neoadjuvant and adjuvant therapy depends on your individual cancer characteristics and stage. Your pathology report and molecular testing results are crucial—they help your team determine the most effective approach for YOUR specific situation.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.